{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:57:41Z","timestamp":1793505461948,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100021772","name":"Deanship of Scientific Research, University of Jordan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019725","name":"Deanship of Scientific Research, Prince Sattam bin Abdulaziz University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007614","name":"Al Jouf University","doi-asserted-by":"publisher","award":["269\/39"],"award-info":[{"award-number":["269\/39"]}],"id":[{"id":"10.13039\/501100007614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ejphar.2019.172638","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T11:49:09Z","timestamp":1567511349000},"page":"172638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme"],"prefix":"10.1016","volume":"862","author":[{"given":"Mohamed","family":"Abouelkheir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek H.","family":"El-Metwally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.172638_bib1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejphar.2019.172638_bib2","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1111\/j.1742-4658.2011.08276.x","article-title":"Structural characterization of angiotensin I-converting enzyme in complex with a selenium analogue of captopril","volume":"278","author":"Akif","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejphar.2019.172638_bib3","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2019.172638_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2019.172638_bib5","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1016\/j.bmcl.2009.05.079","article-title":"Effect of varying chain length between P(1) and P(1') position of tripeptidomimics on activity of angiotensin-converting enzyme inhibitors","volume":"19","author":"Chaudhary","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2019.172638_bib6","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/0006-2952(71)90292-9","article-title":"Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung","volume":"20","author":"Cushman","year":"1971","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172638_bib17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes","volume":"355","author":"DREAM Trial Investigators","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2019.172638_bib7","series-title":"In Vitro and in Silico Inhibition of Angiotensin-Converting Enzyme by Carbohydrates and Cyclitols, Chemical. Papers","first-page":"37","author":"Endringer","year":"2014"},{"key":"10.1016\/j.ejphar.2019.172638_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.vph.2006.05.002","article-title":"Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists","volume":"45","author":"Erbe","year":"2006","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172638_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vph.2011.05.001","article-title":"Cardiovascular effects of DPP-4 inhibition: beyond GLP-1","volume":"55","author":"Fadini","year":"2011","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172638_bib10","doi-asserted-by":"crossref","first-page":"E435","DOI":"10.1152\/ajpendo.00391.2014","article-title":"Modulation of glucose metabolism by the renin-angiotensin-aldosterone system","volume":"308","author":"Favre","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2019.172638_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/bdd.662","article-title":"Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats","volume":"30","author":"Fuchs","year":"2009","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.ejphar.2019.172638_bib12","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2337\/diacare.28.9.2261","article-title":"The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes","volume":"28","author":"Gillespie","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2019.172638_bib13","doi-asserted-by":"crossref","first-page":"F414","DOI":"10.1152\/ajprenal.00174.2007","article-title":"Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule","volume":"294","author":"Girardi","year":"2008","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.ejphar.2019.172638_bib14","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/jf5002606","article-title":"Kinetics and molecular docking studies of the inhibitions of angiotensin converting enzyme and renin activities by hemp seed (Cannabis sativa L.) peptides","volume":"62","author":"Girgih","year":"2014","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejphar.2019.172638_bib15","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2019.172638_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2012.11.009","article-title":"Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes","volume":"100","author":"Herzlinger","year":"2013","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2019.172638_bib18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s10930-013-9492-3","article-title":"Molecular dynamics simulation and molecular docking studies of Angiotensin converting enzyme with inhibitor lisinopril and amyloid Beta Peptide","volume":"32","author":"Jalkute","year":"2013","journal-title":"Protein J."},{"key":"10.1016\/j.ejphar.2019.172638_bib19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.peptides.2010.02.022","article-title":"Arachin derived peptides as selective angiotensin I-converting enzyme (ACE) inhibitors: structure-activity relationship","volume":"31","author":"Jimsheena","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2019.172638_bib20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1042\/CS20180031","article-title":"The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin","volume":"132","author":"Kanasaki","year":"2018","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejphar.2019.172638_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2174\/156802607780091064","article-title":"Molecular recognition of ligands in dipeptidyl peptidase IV","volume":"7","author":"Kuhn","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172638_bib22","first-page":"361","article-title":"Potential linagliptin-induced renal impairment","volume":"3","author":"Kutoh","year":"2012","journal-title":"JMC"},{"key":"10.1016\/j.ejphar.2019.172638_bib23","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.athoracsur.2004.05.046","article-title":"Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient","volume":"79","author":"Lazar","year":"2005","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.ejphar.2019.172638_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjhyper.2004.07.001","article-title":"Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition","volume":"18","author":"Leiter","year":"2005","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2019.172638_bib25","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.procbio.2014.02.007","article-title":"In vitro and in vivo ACE inhibitory of pistachio hydrolysates and in silico mechanism of identified peptide binding with ACE","volume":"49","author":"Li","year":"2014","journal-title":"Process Biochem."},{"key":"10.1016\/j.ejphar.2019.172638_bib26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jcjd.2014.05.001","article-title":"Blood pressure-lowering effects of incretin-based diabetes therapies","volume":"38","author":"Lovshin","year":"2014","journal-title":"Can. J. Diabetes"},{"key":"10.1016\/j.ejphar.2019.172638_bib27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/HYPERTENSIONAHA.110.156554","article-title":"Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans","volume":"56","author":"Marney","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2019.172638_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/106002809002400511","article-title":"Angiotensin-converting enzyme inhibitors and renal function","volume":"24","author":"Mason","year":"1990","journal-title":"DICP"},{"key":"10.1016\/j.ejphar.2019.172638_bib29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2337\/dc12-0706","article-title":"Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study","volume":"36","author":"McGill","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2019.172638_bib30","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2337\/diabetes.53.3.654","article-title":"Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects","volume":"53","author":"Meier","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2019.172638_bib31","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0091270008316885","article-title":"Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension","volume":"48","author":"Mistry","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172638_bib32","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1210\/en.2011-0183","article-title":"Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARgamma target gene regulation","volume":"153","author":"Muller-Fielitz","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2019.172638_bib33","first-page":"5695641","article-title":"Acute kidney injury associated with linagliptin","author":"Nandikanti","year":"2016","journal-title":"Case. Rep. Endocrinol."},{"key":"10.1016\/j.ejphar.2019.172638_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1620\/tjem.223.133","article-title":"Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes","volume":"223","author":"Ogawa","year":"2011","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.ejphar.2019.172638_bib35","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/HJH.0b013e328341939d","article-title":"Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats","volume":"29","author":"Pacheco","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2019.172638_bib36","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1016\/j.bmcl.2011.05.033","article-title":"The molecular mechanisms of interactions between bioactive peptides and angiotensin-converting enzyme","volume":"21","author":"Pan","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2019.172638_bib37","first-page":"175","article-title":"ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients","volume":"6","author":"Paolisso","year":"1992","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejphar.2019.172638_bib38","first-page":"195","article-title":"Cardiovascular effects of dipeptidyl peptidase-4 inhibitors","volume":"19","author":"Papagianni","year":"2015","journal-title":"Hippokratia"},{"key":"10.1016\/j.ejphar.2019.172638_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0008-6363(98)00077-7","article-title":"Lessons from rat models of hypertension: from Goldblatt to genetic engineering","volume":"39","author":"Pinto","year":"1998","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2019.172638_bib40","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.bmcl.2017.04.036","article-title":"Approaches towards the development of chimeric DPP4\/ACE inhibitors for treating metabolic syndrome","volume":"27","author":"Sattigeri","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2019.172638_bib41","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1262-3636(07)70147-7","article-title":"Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms","volume":"30","author":"Scheen","year":"2004","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ejphar.2019.172638_bib42","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the council on the kidney in cardiovascular disease and the council for high blood pressure Research of the American heart association","volume":"104","author":"Schoolwerth","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2019.172638_bib43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.vph.2011.03.001","article-title":"Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways","volume":"55","author":"Shah","year":"2011","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172638_bib44","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2337\/diabetes.53.4.989","article-title":"Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat","volume":"53","author":"Tikellis","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2019.172638_bib45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s13340-017-0320-4","article-title":"Different effects of linagliptin and sitagliptin on blood pressure and renal function in Japanese patients with type 2 diabetes mellitus","volume":"8","author":"Tojikubo","year":"2017","journal-title":"Diabetol. Int."},{"key":"10.1016\/j.ejphar.2019.172638_bib46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0162-3109(99)00087-9","article-title":"The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor","volume":"44","author":"Ura","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.ejphar.2019.172638_bib47","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/jm030091l","article-title":"1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties","volume":"46","author":"Villhauer","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172638_bib48","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/14756366.2014.1002402","article-title":"Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions","volume":"30","author":"Watanabe","year":"2015","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172638_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.peptides.2014.07.026","article-title":"A novel angiotensin-capital I, Ukrainian converting enzyme (ACE) inhibitory peptide from gastrointestinal protease hydrolysate of silkworm pupa (Bombyx mori) protein: biochemical characterization and molecular docking study","volume":"68","author":"Wu","year":"2015","journal-title":"Peptides"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919305904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919305904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:05:24Z","timestamp":1762142724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919305904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":49,"alternative-id":["S0014299919305904"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172638","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172638"}}